Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pentosan polysulfate - Paradigm Biopharma

Next Previous
Drug Profile

Pentosan polysulfate - Paradigm Biopharma

Alternative Names: Pentosan polysulfate sodium - Paradigm Biopharma; PPS - Paradigm Biopharma; Rhinosul; ZILOSUL; Zilosul

Latest Information Update: 15 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Glycan Biosciences; Griffith University
  • Developer Griffith University; Paradigm Biopharma
  • Class Analgesics; Anti-inflammatories; Antiallergics; Anticoagulants; Antihyperlipidaemics; Antiretrovirals; Antithrombotics; Antivirals; Glycosaminoglycans; Polymers; Polysaccharides; Small molecules; Sulfuric acids
  • Mechanism of Action Cell membrane permeability inhibitors; Enzyme inhibitors; Non-nucleoside reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Pain
  • Phase II Mucopolysaccharidosis VI; Ross River virus infections; Seasonal allergic rhinitis
  • Phase I/II Mucopolysaccharidosis I; Oedema
  • Preclinical Osteoarthritis
  • No development reported Allergic asthma; Allergic rhinitis; Chikungunya virus infections; Chronic obstructive pulmonary disease

Most Recent Events

  • 08 Apr 2025 Paradigm Biopharmaceuticals plans a phase III trial in Pain (SC, Injection) in May 2025 (NCT06917404)
  • 10 Nov 2023 Preclinical trials in Osteoarthritis in Australia (SC) prior to November 2023
  • 10 Nov 2023 Pharmacodynamics and adverse events data from preclinical studies in Osteoarthritis presented at the ACR Convergence 2023 (ACR-ARP-2023) )

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top